MTX325 moving into clinical testing in the coming months
The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has given Mission Therapeutics clearance to launch a Phase 1 clinical trial testing MTX325, its experimental oral therapy for Parkinson’s disease. “The MHRA’s authorisation marks a major step forward in our mission to develop MTX325 as a disease-modifying therapy for…